ArticleInternational journal of retina and vitreous2025
Central retinal vein occlusion following intravitreal injections: a case series highlighting multifactorial risk.
Article in International journal of retina and vitreous, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systemic and ocular complications related to intravitreal administration of anti-VEGF agents.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionIntravitreal injections are standard treatment for various manifestations of age-related macular degeneration (AMD) but are associated with rare complications, including central retinal vein occlusion (CRVO). This report describes three cases of CRVO following intravitreal injections in patients with AMD.
methodsRetrospective case series describing three patients with AMD who developed CRVO after intravitreal injections.
resultsCRVO occurred after ranibizumab (Lucentis, South San Francisco, CA), brolucizumab (Beovu, Novartis, Basel, Switzerland), and pegcetacoplan (Syfovre, Apellis, Waltham, MA) injections. All patients had multiple systemic vasculopathic risk factors. No intraocular inflammation or vasculitis was observed on examination, and fluorescein angiography was not performed. Visual outcomes were poor despite anti-VEGF treatment. None of the three patients developed neovascular glaucoma under our observation. The timing relationship between injection and CRVO varied, and causality could not be established.
conclusionCRVO may occur after intravitreal injections across different drug classes, even with agents that have low inflammatory potential. These cases highlight the multifactorial nature of this event and the importance of considering systemic vasculopathy when evaluating post-injection complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.